In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 8, 1996, Pages 696-698

  Crokaert, F ^a   Aoun, M ^a   Duchateau, V ^a   Grenier, P ^a   Vanderraies, A ^a   Klastersky, X ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; FLEROXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; ASPIRATION PNEUMONIA; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

EID: 0029839670     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691164     Document Type: Article

References (10)

1. Ball AR Tillotson GS: Lower respiratory tract infection therapy - The role of ciprofloxacin. Journal of International Medical Research 1995, 23: 315-327.
2. Roblin PM, Montalban G, Hammerschlag MR: In vitro activity of OPC-17116, a new quinolone, ofloxacin and sparfloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 1994, 38: 1402-1403.
3. Piddock LJV: New quinolones and gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1994, 38: 163-169.
4. Wise R, Mortiboy D, Child J, Andrews JM: Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP99,219). Antimicrobial Agents and Chemotherapy 1996, 40: 47-49.
5. Girard AE, Girard D, GootzTD, Faiella JA, Cimochowski CR: In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activity against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 1995, 39:2210-2216.
6. Paris MM, Hickey SM, Trujilo M, Shelton S, McCracken GH: Evaluation of CP-99,219, anewfluoroquinolone, for treatment of experimental penicillin- and cephalosporinresistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 1995, 39: 1243-1246.
7. Baron EJ, Weissfeld AS, Fuselier PA, Brenner DJ: Classification and identification of bacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC,: Yolken RH (ed): Manual of clinical microbiology. American Society for Microbiology, Washington DC, 1995, p. 249-264.
8. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7A3. NCCLS, Vilianova, PA, 1993.
9. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Approved standard M100-S3. NCCLS, Villanova, PA., 1994.
10. Neu H, Chin N.-X.: In vitro activity of CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615-2622.